Centrexion Corporation

Baltimore-based pharmaceutical development company seeking to develop a new class of therapeutics that stops pain at its source. Non-opioid clinical stage product candidates selectively deactivate pain fibers to provide patients with long lasting relief. Our pipeline targets major unmet needs in the treatment of severe pain caused by human osteoarthritis, or OA, and canine OA, nerve injury, and herpes zoster viral infection.